PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate Update
Licensing Key IP from the Massachusetts General Hospital to create improved clinical decision-making tools
The Company is excited to finalize its license for this unique intellectual property. The patent will allow to PDTx to further
enhance the value of the data they generate and expand business.”
NEW YORK, NEW YORK, USA, April 6, 2022 /EINPresswire.com/ -- PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate Update — PDTx board of directors member and Lucius Partners founder James Ahern
Licensing Key IP from the Massachusetts General Hospital to create improved clinical decision-making tools.
Utilizing proprietary workflows and algorithms to begin generating the data required to
advance the platform technology.
Lucius Partners, LLC today announced that its portfolio company, PD
Theranostics, Inc. (PDTx), announced a corporate update and reviewed recent progress developing its
theranostic platform to address unmet medical needs in important patient populations.
First, the company reported that it has signed an agreement with the Massachusetts General Hospital
(MGH) to secure foundational intellectual property to further develop the Company’s theranostic
platform.
Additionally, PDTx is actively using analysis of prostate tissue samples to finalize the initial optimization
and standardization of its proprietary prognostic imaging workflows and Artificial Intelligence (AI)
algorithms. The AI is designed to enhance interpretation of existing pathology results and provide novel
predictive data to anchor and improve clinical decision-making. The unique, patient specific information,
which may allow healthcare providers to better tailor treatments for their patients, is currently
unavailable in clinical practice.
Dr. Mark Poznansky, scientific co-founder of PDTx stated, “Providing novel, clinical decision-enabling
data with the highest utility to pathologists and clinicians drives our research efforts. This intellectual
property will support the efforts of PDTx to accelerate and expand its science and tools to help patients
receive the most appropriate treatments. While our initial focus is on creating predictive artificial
intelligence (A)I solutions in solid tumors and infections, we believe this technology has the potential to
have a transformative impact on patient care in many medical conditions.” Dr. Poznansky is also
Director of the Vaccine and Immunotherapy Center at MGH, and Professor of Medicine at Harvard
Medical School.
“PDTx continues to improve and scale our proprietary imaging AI platform by generating initial data
based on prostate tissue samples. This data will advance our identification of cellular signatures and
prognostic biomarkers that could indicate various disease risks and treatments,” said Patrick Gallagher,
Chief Executive Officer of PD Theranostics, Inc. “Licensing this foundational patent from MGH will allow
us to further explore the potential for AI to maximize clinical predictiveness while optimizing system
flexibility to address tissue samples across multiple disease states. Generating actionable data that is
derived at the cellular level has the potential, we believe, to be a significant step toward improved
patient outcomes.”
“The Company is excited to finalize its license for this unique intellectual property,” said PDTx board of
directors member and Lucius Partners founder James Ahern. “The patent will allow to PDTx to further
enhance the value of the data they generate and expand business opportunities. We believe that our
intellectual property strategy will drive the development of a broad portfolio of computational
pathology applications and create shareholder value.”
About PD Theranostics, Inc.
PD Theranostics is developing AI guided algorithms while leveraging proprietary workflows and methods
utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific
targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and
complications of diabetes including diabetic foot ulcers. Please visit www.pdtheranostics.com for more
information.
About Lucius Partners, LLC
Lucius Partners is a consultancy that provides a broad suite of services to help healthcare companies
grow, achieve milestones and generate value for their shareholders.
Lucius Partners, LLC
12 E. 49th St., 11th Floor, New York, NY 10017
Contact:
Patrick Gallagher, CEO
PD Theranostics, Inc.
pgallagher@luciuspartnersllc.com
Matthew Duffy, President
PD Theranostics, Inc.
mduffy@luciuspartnersllc.co
Matthew Duffy
PD Theranostics, Inc.
pgallagher@luciuspartnersllc.com
